Short-term Function and Pain After Treatment for Dupuytren's Disease

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

60 participants

Study Classification

OBSERVATIONAL

Study Start Date

2014-07-31

Study Completion Date

2017-11-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study will evaluate short-term pain and function associated with percutaneous needle aponeurotomy (PNA) and injections of the enzyme collagenase clostridium histolyticum in patients with Dupuytren's disease. Scores on outcome measures will be compared between groups to determine whether treatments differ in terms of hand function and pain during the early post-treatment period.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Collagenase in the Treatment of Dupuytrens Disease

NCT00260429

Dupuytren's Disease

COMPLETED PHASE3

Repurposing Anti-TNF for Treating Dupuytren's Disease

NCT03180957

Dupuytren's Disease

COMPLETED PHASE2

Registry of Dupuytren's Contracture Treatment Outcomes

NCT01567397

Dupuytren's Disease

COMPLETED

Efficacy of Botulinum Toxin In Scleroderma-Associated Raynaud's Syndrome

NCT02165111

Scleroderma Raynaud's Syndrome

COMPLETED PHASE3

Validation of Two New Questionnaires for Dupuytren's Disease

NCT01446432

Dupuytren's Disease

UNKNOWN

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Percutaneous needle aponeurotomy (PNA) and injections of the enzyme collagenase clostridium histolyticum are two non-invasive treatment options for patients with Dupuytren's disease. While PNA has been offered for decades, injectable collagenase is relatively new. The effectiveness of each treatment has been compared in the literature; however, recovery, in terms of pain and short-term function has not been formally evaluated. The objective of this study is to objectively compare short-term function and pain outcomes associated with each of these two procedures in patients presenting with untreated Dupuytren's disease.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Dupuytren Disease

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Percutaneous Needle Aponeurotomy

Patients who choose to undergo percutaneous needle aponeurotomy (PNA) for primary treatment of Dupuytren's disease

Percutaneous Needle Aponeurotomy

Intervention Type PROCEDURE

single procedure (day 0)

Xiaflex

Patients who choose to receive Collagenase clostridium histolyticum injection (drug name Xiaflex) for primary treatment of Dupuytren's disease.

Collagenase clostridium histolyticum

Intervention Type DRUG

Xiaflex injection into palpable cords (day 0), physical manipulation (day 7)

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Percutaneous Needle Aponeurotomy

single procedure (day 0)

Intervention Type PROCEDURE

Collagenase clostridium histolyticum

Xiaflex injection into palpable cords (day 0), physical manipulation (day 7)

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

needle aponeurotomy fasciotomy Xiaflex

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Adult
* Dupuytren's disease diagnosis
* Consented to either percutaneous needle aponeurotomy or Xiaflex injection (patient choice)
* Able to read/write/speak English
* Must have an email address